• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Advertise
  • Subscribe

MassDevice

The Medical Device Business Journal — Medical Device News & Articles | MassDevice

  • Latest News
  • Technologies
    • Artificial Intelligence (AI)
    • Cardiovascular
    • Orthopedics
    • Neurological
    • Diabetes
    • Surgical Robotics
  • Business & Finance
    • Wall Street Beat
    • Earnings Reports
    • Funding Roundup
    • Mergers & Acquisitions
    • Initial Public Offering (IPO)
    • Legal News
    • Personnel Moves
    • Medtech 100 Stock Index
  • Regulatory & Compliance
    • Food & Drug Administration (FDA)
    • Recalls
    • 510(k)
    • Pre-Market Approval (PMA)
    • MDSAP
    • Clinical Trials
  • Special Content
    • Special Reports
    • In-Depth Coverage
    • DeviceTalks
  • Podcasts
    • MassDevice Fast Five
    • DeviceTalks Weekly
    • OEM Talks
      • AbbottTalks
      • Boston ScientificTalks
      • DeviceTalks AI
      • IntuitiveTalks
      • MedtechWOMEN Talks
      • MedtronicTalks
      • Neuro Innovation Talks
      • Ortho Innovation Talks
      • Structural Heart Talks
      • StrykerTalks
  • Resources
    • About MassDevice
    • DeviceTalks
    • Newsletter Signup
    • Leadership in Medtech
    • Manufacturers & Suppliers Search
    • MedTech100 Index
    • Videos
    • Webinars
    • Whitepapers
    • Voices
Home » NeuroMetrix swings to Q4 black on warrants revaluation

NeuroMetrix swings to Q4 black on warrants revaluation

February 10, 2010 By MassDevice staff

A revaluation of warrants and a change in reimbursement policy helped produce fourth-quarter profits and hope for future top-line growth for NeuroMetrix Inc. (NSDQ:NURO).

The Waltham, Mass.-based nerve conduction testing equipment maker posted net income of $363,231 for the three months ended Dec. 31, 2009, or 2 cents per share, compared with a net loss of $4.1 million, or 30 cents per share, during the fourth quarter of 2008. NeuroMetrix cited a $2.2 million revaluation of warrants for the swing into the black, connected with a financing move it made last September. The company won commitments from institutional investors to buy about $18.7 million worth of its stock — 8,816,521 shares and warrants to purchase up to 8,375,695 additional shares — in a private placement for $2.12 per share. Absent the revaluation, the company posted losses from operations of $1.9 million.

Top-line results for the quarter were less satisfactory. NeuroMetrix posted revenues of $6.2 million, down 13.3 percent compared with $7.2 million during Q4 2008.

For the full year, the company reported net losses of $11.9 million, or 71 cents per share, on revenues of $26.1 million, compared with net losses of $27.7 million, or $2.02 per share, on revenues of $31.1 million during 2008.

But the company’s outlook got a boost from a fourth-quarter move by the Centers for Medicare and Medicaid Services to publish a new reimbursement code covering nerve conduction studies performed with devices like NeuroMetrix’s flagship NC-stat system. The code “may streamline Medicare reimbursement for medically appropriate nerve conduction studies performed using the NC-stat System, and could also be a positive influence on reimbursement by commercial insurers,” according to a company press release.

President and CEO Shai Gozani said the new code should benefit NeuroMetrix over the long term, but because it’s lower than prior codes, over the short term it will mean changes to the company’s business model and “downward pressure on revenues and margins.”

That said, NeuroMetrix took steps to increase the number of doctors using its equipment and consumables. It reorganized its North American sales force into two groups, one focused on primary care, internal medicine, endocrinology and rheumatology practices and the other concentrated on neurology, physical medicine and rehabilitation and orthopedics practices.

Gozani said a range of factors, including reimbursement changes, lower patient visit rates and the healthcare reform debate, “make 2010 a difficult year to predict.” NeuroMetrix did not provide guidance for the first quarter or 2010.

Filed Under: Business/Financial News, MassDevice Earnings Roundup, Neurological, News Well Tagged With: Neurometrix

More recent news

  • GE HealthCare launches next-gen intraoperative ultrasound
  • Philips launches new point-of-care ultrasound system
  • Medtronic to invest $50M in India Diabetes center
  • Corvia Medical raises $55M as it seeks FDA nod for atrial shunt
  • Penumbra completes enrollment in pulmonary embolism trial

Primary Sidebar

“md
EXPAND YOUR KNOWLEDGE AND STAY CONNECTED
Get the latest med device regulatory, business and technology news.

DeviceTalks Weekly

See More >

MEDTECH 100 Stock INDEX

Medtech 100 logo
Market Summary > Current Price
The MedTech 100 is a financial index calculated using the BIG100 companies covered in Medical Design and Outsourcing.
MDO ad

Footer

MASSDEVICE MEDICAL NETWORK

DeviceTalks
Drug Delivery Business News
Medical Design & Outsourcing
Medical Tubing + Extrusion
Drug Discovery & Development
Pharmaceutical Processing World
MedTech 100 Index
R&D World
Medical Design Sourcing

DeviceTalks Webinars, Podcasts, & Discussions

Attend our Monthly Webinars
Listen to our Weekly Podcasts
Join our DeviceTalks Tuesdays Discussion

MASSDEVICE

Subscribe to MassDevice E-Newsletter
Advertise with us
About
Contact us

Copyright © 2025 · WTWH Media LLC and its licensors. All rights reserved.
The material on this site may not be reproduced, distributed, transmitted, cached or otherwise used, except with the prior written permission of WTWH Media.

Privacy Policy